Clozapine Increases Response After One Failed Antipsychotic in Early Psychosis

Rethinking the Timeline for Treatment Resistance in Early Psychosis

Approximately one-quarter of patients experiencing first-episode psychosis will develop treatment-resistant schizophrenia during the early stages of their illness [1]. Current clinical guidelines generally recommend sequential trials of standard antipsychotics, reserving clozapine for patients who have failed at least two adequate pharmacological interventions [2]. However, response rates drop precipitously with each subsequent medication change, falling from roughly 53% in the first stage to just 26% in the second [2]. This diminishing return has prompted researchers to question whether identifying treatment resistance earlier and expediting clozapine therapy could prevent prolonged periods of uncontrolled symptoms [3]. A recent randomized clinical trial now provides direct evidence on the efficacy of moving clozapine up the treatment algorithm to immediately follow a single failed antipsychotic trial.

A Two-Phase Sequential Trial Design

To provide actionable data on the optimal sequencing of antipsychotics, researchers conducted a sequential, assessor-blind trial with two randomizations across seven centers in China between February 2019 and October 2022. The study evaluated whether switching to clozapine is effective in patients with first-episode psychosis who have not responded to one previous antipsychotic drug. A total of 762 participants were randomized, yielding a final cohort of 654 eligible individuals with a mean age of 26.9 years (standard deviation of 7.5 years) and an even gender distribution of 328 male patients (50.2%). Included participants were aged 16 to 45 years and diagnosed with first-episode psychosis, specifically encompassing schizophrenia, schizophreniform disorder, or schizoaffective disorder. In the first phase of the trial, these patients were randomized to receive oral olanzapine, risperidone, amisulpride, aripiprazole, or perphenazine for eight weeks. Nonresponders from this initial treatment period were then rerandomized in phase two to receive olanzapine, amisulpride, or clozapine for an additional eight weeks. Patients who achieved clinical improvement during either phase entered a one-year naturalistic follow-up to monitor long-term stability. The investigators established two primary outcomes to evaluate the interventions. The first was symptomatic response, defined as the proportion of patients achieving a 40% or greater reduction in the Positive and Negative Syndrome Scale total score, a standard clinical tool used to quantify symptom severity. The second primary outcome was time to all-cause discontinuation, defined as the cessation of antipsychotic drugs for any reason, which serves as a proxy for medication tolerability and overall effectiveness.

Phase 1 Outcomes: First-Line Efficacy

During the initial eight-week treatment period, patient retention and overall clinical improvement were robust. Of the eligible participants, 556 (85.4%) completed the first phase. Across the entire cohort, 359 patients (55.1%) responded to treatment in phase one, successfully achieving the predefined threshold of a 40% or greater reduction in symptom severity. Efficacy varied considerably depending on the specific agent prescribed. Phase one response rates were highest for risperidone at 63.4% (83 of 131 patients), amisulpride at 61.8% (81 of 131), and olanzapine at 60.5% (78 of 129). Conversely, the other two medications demonstrated lower efficacy, with response rates of 45.7% (59 of 129) for perphenazine and 44.3% (58 of 131) for aripiprazole. The researchers determined that the difference in response rates across the five drugs was statistically significant (chi-square = 18.3; P = .001). Ultimately, the data showed that the majority of patients with first-episode psychosis responded to an initial antipsychotic drug trial. For practicing clinicians, these findings provide clear guidance on initial medication selection, suggesting that risperidone, amisulpride, and olanzapine may offer superior initial symptom control compared to aripiprazole and perphenazine before evaluating patients for treatment resistance.

Phase 2 Outcomes: Clozapine as a Second-Line Agent

For the second stage of the trial, the investigators focused on the cohort of patients who did not achieve adequate symptom relief during the initial eight weeks. In phase two, 111 nonresponders were rerandomized to receive a different medication. The distribution of these patients included 41 taking olanzapine, 38 taking amisulpride, and 32 taking clozapine. Patient retention remained high during this subsequent eight-week period, as a total of 92 patients (82.9%) completed phase two. When evaluating clinical improvement during this second step, the researchers found that response was achieved by 20 patients (62.5%) taking clozapine, compared to 17 (44.7%) taking amisulpride and 13 (31.7%) taking olanzapine. The data demonstrated that the difference in phase two response rates between clozapine, amisulpride, and olanzapine was statistically significant (chi-square = 6.9; P = .03). Consequently, in those who initially did not respond to antipsychotic treatment, clozapine was significantly more efficacious than olanzapine and amisulpride based on the standardized symptom rating criteria. These findings challenge the traditional algorithm that delays clozapine until multiple medications have proven ineffective. For psychiatrists and primary care physicians managing early schizophrenia, the study provides concrete evidence to consider using clozapine as the immediate next sequential treatment after a patient fails an adequate trial with one traditional antipsychotic. By moving clozapine earlier in the treatment sequence, physicians may capture a higher response rate, minimize the neurotoxic burden of active disease, and prevent prolonged periods of uncontrolled psychosis in their patients.

References

1. Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis.. The British journal of psychiatry : the journal of mental science. 2022. doi:10.1192/bjp.2021.61

2. O'Donoghue B, Piacenza F, Plapp H, Siskind D, Lyne J. Response rates to sequential trials of antipsychotic medications according to algorithms or treatment guidelines in psychotic disorders. A systematic review and meta-analysis.. Schizophrenia research. 2024. doi:10.1016/j.schres.2024.02.035

3. Smart SE, Kępińska AP, Murray R, MacCabe JH. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychological Medicine. 2019. doi:10.1017/s0033291719002083